

GSK Irvine Antibiotics Business Unit

Excellence, Partnership, Passion



Introduction

Established in 1973 GSK Irvine has over thirty-seven years experience and operational expertise as a primary manufacturing site. GSK Irvine supplies a significant proportion of the requirement for GSK's global secondary production operations and third party customers.

It is one of the world's major producers of antibiotics derived from penicillin. GSK Irvine is situated in the South West of Scotland close to all major rail, road, air and sea routes.



Key capabilities

Irvine is recognised as a centre of excellence in biotechnology, fermentation and extraction technology, and process automation. This FDA and MHRA approved facility has an excellent reputation on supply and delivery.

Operational technology employed at Irvine includes large scale fermentation, continuous extraction, membrane technology, solvent extraction, crystallisation, drying and blending. The facility has its own steam and nitrogen generation capability as well as a dedicated waste water treatment and solvent recovery plant.





Products & Markets

The Irvine site produces a range of antibiotic products:

- **6-Amino Penicillic Acid (6APA)**
- **Potassium Clavulanate**
- **Potassium Amoxicillin Blends**
- **Potassium Clavulanate Avicel Blends**
- **Potassium Clavulanate Syloid Blends**

As a global supply site, Irvine distributes products to both GSK's global secondary production operations and third party customers worldwide. The main markets which Irvine supplies are UK, Singapore, USA and the Middle East.





GlaxoSmithKline

Irvine



Main reception



GlaxoSmithKline

www.gsk.com